Thierry Wilbrandt, MD
Ophthalmology · Indianapolis, INNPI 1609867597
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,310 of the $13,250 with a category attached, or 62.7%. 28 manufacturers reported payments, led by Carl Zeiss Meditec Digital Innovations LLC at 34.8% of the total. Reporting peaked in 2024 at $6,319 and has fallen 74.9% since, to $1,583 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $64.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec Digital Innovations LLC$5K
- Alcon$3K
- Mallinckrodt Hospital Products Inc.$989
- Sight Sciences, Inc.$913
- AbbVie$739
- Bausch & Lomb Americas Inc.$563
- plus $3K from 22 others
What the payments were for
- Food & beverage$8,31063%
- Education$1881%
- Other$4,75236%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec Digital Innovations LLC | 1 | $4,612 |
| Alcon | 44 | $2,625 |
| Mallinckrodt Hospital Products Inc. | 23 | $989 |
| Sight Sciences, Inc. | 15 | $913 |
| AbbVie(2 entities) | 29 | $739 |
| Bausch & Lomb Americas Inc. | 12 | $563 |
| Sun Pharmaceutical Industries Inc. | 13 | $357 |
| Aerie Pharmaceuticals, Inc. | 5 | $323 |
| Eyevance Pharmaceuticals LLC | 2 | $314 |
| Carl Zeiss Meditec, Inc. | 2 | $271 |
| Ocular Therapeutix, Inc. | 9 | $240 |
| Harrow Eye, LLC | 5 | $206 |
| Oyster Point Pharma, Inc. | 10 | $184 |
| Amgen(2 entities) | 4 | $173 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $142 |
| ANI Pharmaceuticals, Inc. | 4 | $101 |
| Kala Pharmaceuticals, Inc. | 5 | $85 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $75 |
| Ivantis, Inc | 3 | $56 |
| NEW World Medical,inc. | 3 | $54 |
| Astellas Pharma US Inc | 2 | $46 |
| Novartis | 3 | $45 |
| Dompe US, Inc. | 2 | $43 |
| Rayner Intraocular Lenses Limited | 1 | $28 |
| Glaukos Corporation | 1 | $25 |
| Thea Pharma Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $12 |
| Rxsight Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERACITY SURGICAL$4,612
- OMNI(R) SURGICAL SYSTEM (US)$586
- Clareon$562
- ACTHAR$388
- Hydrus Microstent$376
- ARGOS$354
- Tobradex ST$296
- DURYSTA$256
- Rhopressa$226
- Rocklatan$226
- AcrySof$225
- CIRRUS HD-OCT$211
- IOLMaster 500$211
- VisuMax$211
- CALLISTO eye$211
- ARTEVO 800$211
- TEPEZZA$125
- VYZULTA$124
- CEQUA$120
- Voyager DSLT$114
How this compares
$13,250 in reported general payments places this provider in the 90th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 30 | $36,018 |
| LumiganBimatoprost | 31 | $16,177 |
| Cyclosporine | 11 | $15,732 |
| MieboPerfluorohexyloctane/Pf | 16 | $12,271 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $7,515 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,375 |
| Prednisolone Acetate | 53 | $2,579 |
| Ketorolac Tromethamine | 51 | $2,000 |
| Latanoprost | 139 | $1,357 |
| Timolol Maleate | 30 | $633 |
| Brimonidine Tartrate | 61 | $627 |
| Diclofenac Sodium | 52 | $604 |
| Dorzolamide Hcl | 27 | $392 |
| Ciprofloxacin Hcl | 37 | $391 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $739 | $56,57072 claims |
| Bausch & Lomb Americas Inc.Miebo | $563 | $12,27116 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $323 | $7,51515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
- Shaohui LiuIndianapolis$19K
- John LatonaIndianapolis$18K
- William WhitsonIndianapolis$15K
- Anthony LombardoIndianapolis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.